This offering should be surprising to nobody. The only reason SRPT isn't seeking more than $259M is that they plan to monetize their newly-awarded FDA priority-review voucher.
*Assuming exercise of underwriter’s option.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.